Share on StockTwits

Merck & Co (NYSE:MRK)‘s stock had its “buy” rating reaffirmed by investment analysts at TheStreet in a note issued to investors on Monday, American Banking News reports.

The analysts wrote, “Merck (MRK) has been reiterated by TheStreet Ratings as a buy with a ratings score of B+. The company’s strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, good cash flow from operations, expanding profit margins and increase in stock price during the past year. We feel these strengths outweigh the fact that the company has had sub par growth in net income.”

Merck & Co (NYSE:MRK) last announced its earnings results on Monday, October 28th. The company reported $0.92 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.88 by $0.04. The company had revenue of $11.03 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. The company’s quarterly revenue was down 4.0% on a year-over-year basis.

MRK has been the subject of a number of other recent research reports. Analysts at Jefferies Group raised their price target on shares of Merck & Co from $51.00 to $54.00 in a research note to investors on Thursday. They now have a “hold” rating on the stock. Separately, analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co in a research note to investors on Tuesday, December 31st. They now have a $52.00 price target on the stock. Finally, analysts at BMO Capital Markets cut their EPS estimates on shares of Merck & Co in a research note on Friday. They now have an “outperform” rating and a $54.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, six have assigned a hold rating and seven have assigned a buy rating to the stock. The stock has an average rating of “Hold” and a consensus target price of $52.24.

Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.